AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02278094 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Positive Airway Pressure (CPAP)
Description: CPAP regular therapy per day (use ≥ 4 h/day) then continue three to five times a week for a total of 3 months.
Study NCT03025906 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenobarbital
Description: In the PB group, a loading dose of 20 mg/kg (may give an additional 10 mg/kg) begins at a rate of 50 mg/min followed by IV 100 mg q6 h.
Study NCT03025906 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valproate
Description: In the VPA group, a loading dose of 30 mg/kg (may give an additional 15 mg/kg) begins at a rate of 3 mg/kg per min followed by a continuous infusion at a rate of 1-2 mg/kg per hour.
Study NCT04068337 — intervention group
Intervention type: PROCEDURE
Intervention: Aortic root replacement with Freestyle biological prosthesis with and without hemiarch replacement
Description: Aortic root replacement with Freestyle biological prosthesis. Some patients receive additional hemiarch replacement performing an open anastomosis to the aortic arch under antegrade cerebral perfusion through axillary artery. Comparison with patients, who were cannulated and perfused systemically
Study NCT01954979 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abatacept
Description: The study will follow a standard 3+3 design with two escalating doses of abatacept to determine the maximum tolerated dose (MTD): 3 mg/kg (dose level 1) and 10 mg/kg (dose level 2). Dose-limiting toxicities (DLTs) are defined as any Grade 3 or 4 toxicities judged to be probably or definitely related to abatacept.
Study NCT00689767 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CINATRA™ Coronary Stent System
Description: Bare metal cobalt chromium stent implantation
Study NCT00689767 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CINATRA™ ISA 247 Coated Coronary Stent System
Description: Drug coated cobalt chromium stent implantation
Study NCT01556373 — intervention group
Intervention type: OTHER
Intervention: NA : non interventional study
Description: NA : non interventional study
Study NCT01339754 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trabectedin
Description: 1.3 mg/mq as a 3 hour continuous infusion every three weeks
Study NCT01339754 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trabectedin
Description: 1.3 mg/mq as a 3 hour continuous infusion every three weeks until progression
Study NCT00546585 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza A/H7N7 Vaccine
Description: Monovalent subvirion H7N7 vaccine, 4 dose levels of vaccine, each subject will receive 2 doses (7.5, 15, 45, or 90 micrograms); the same dose will be given at Day 0 and Day 28.
Study NCT00546585 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sterile normal saline for injection (0.9%); 0.5 ml volume sodium chloride injection. Subjects will receive 2 doses on Day 0 and Day 28.
Study NCT03210805 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3 Polyunsaturated Fatty Acids Supplementation
Description: 28 days of a commercially available supplement. 4 capsules per day.
Study NCT04154956 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR408701
Description: Pharmaceutical form: Concentrate for solution for intravenous infusion Route of administration: intravenous (IV) infusion
Study NCT04154956 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Pharmaceutical form: Concentrate for solution for intravenous infusion Route of administration: IV infusion
Study NCT05008146 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Baseline [C-11]NOP-1A PET Scan
Description: Radiotracer
Study NCT05008146 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Description: Intravenous, 1mg/Kg
Study NCT05008146 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Post-hydrocortisone [C-11]NOP-1A PET Scan
Description: Radiotracer
Study NCT00223860 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Human chorionic gonadotropin (hCG)
Study NCT00223860 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Luteinizing hormone releasing hormone (LHRH)
Study NCT05354050 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DARE-BV1
Description: 2% Clindamycin 100 MG
Study NCT01516047 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort 1
Description: 125 mg to 2000 mg abiraterone acetate suspension on Day 1
Study NCT01516047 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort 2
Description: 2000 mg abiraterone acetate suspension on Day 1
Study NCT04289818 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health Coaching
Description: Health Coaching as face to face with a coach
Study NCT03620344 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ADH-Me Book and ADHD Informational Brochure
Description: Understanding ADHD information brochure published by American Academy of Pediatrics and a children's book about ADHD condition
Study NCT03620344 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: ADHD Informational Brochure Only
Description: Understanding ADHD information brochure published by American Academy of Pediatrics
Study NCT00918411 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramosetron
Description: oral
Study NCT00918411 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral
Study NCT05319067 — intervention group
Intervention type: OTHER
Intervention: Stool sampling
Description: Stool sample taken at home 24 hours before hospital visit
Study NCT04644250 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: Participants will also receive Toripalimab(240mg) VD 30 min on days 3, 24 and 45，3 cycles in total.
Study NCT04644250 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel liposome/Carboplatin
Description: Participants will receive carboplatin (AUC=2) VD 30min and paclitaxel liposome (50mg/m²) CIV 24h on day 3,10,17,24,31, 5cycles in total.
Study NCT04644250 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-modulated radiotherapy
Description: A total of 41.4 Gy, 23 fractions of 1.8 Gy on Day 1 to 31.
Study NCT01564550 — intervention group
Intervention type: DRUG
Intervention: Insulin
Description: Insulin is given as a constant infusion( 0,6 mU/kg/min) during the hyperinsulinemia period of the study lasting four and a half hour.
Study NCT01564550 — intervention group
Intervention type: DRUG
Intervention: insulin
Description: Insulin is given as a constant infusion( 0,6 mU/kg/min) during the hyperinsulinemia period of the study lasting four and a half hour.
Study NCT01564550 — intervention group
Intervention type: OTHER
Intervention: diet
Description: The subjects ingest a three day isocaloric diet (55 % carbohydrate,30% fat, 15 % protein)prior to the study day.
Study NCT01564550 — intervention group
Intervention type: OTHER
Intervention: no diet
Description: The subjects will ingest a non-restricted diet prior to the study day.
Study NCT00617760 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Group C Meningococcal Polysaccharide-Tetansu Toxoid Conjugate (MenC-TT) vaccine and 7-valent Pneumococcal CRM197-conjugate vaccine (PCV7)
Description: MenC-TT vaccine (0.5 ml) to be administered in the left thigh muscle, PCV7 (0.5 ml) to be administered in the right thigh muscle
Study NCT00617760 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 7-valent Pneumococcal CRM197-conjugate vaccine (PCV7)
Description: PCV7 (0.5 ml) to be administered in the right thigh muscle
Study NCT00617760 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Group C Meningococcal Polysaccharide-Tetansu Toxoid Conjugate (MenC-TT)
Description: MenC-TT vaccine (0.5 ml) to be administered in the left thigh muscle
Study NCT00728390 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-00299804
Description: CP-751,871 at recommended dose on Day 1 and 2 of cycle 1, then on Day 1 every 3 weeks; and PF-00299804 orally at recommended dose once daily.
Study NCT02965950 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: I.v. infusion
Study NCT04170738 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adderall
Description: 3 weeks of Adderall
Study NCT03431831 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention Control
Description: diet recommendations of 1200 calorie limit for women daily and 1400 limit for men daily. Decreased foods that are high sugar, highly processed, low nutrient simple carbohydrates. Increased foods that are whole foods, lean proteins, complex carbohydrates and healthy fats. Switch from high calorie drinks to water for beverages.
Study NCT03431831 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intervention Control
Description: diet recommendations of 1200 calorie limit for women daily and 1400 limit for men daily. Decreased foods that are high sugar, highly processed, low nutrient simple carbohydrates. Increased foods that are whole foods, lean proteins, complex carbohydrates and healthy fats. Switch from high calorie drinks to water for beverages.
Study NCT03431831 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Counselling
Description: Usual care as listed in comparator intervention plus motivational interviewing to identify areas of barriers and how to overcome them, to help patient set achievable food, physical activity and beverage goals for themselves weekly and monthly. To identify whether knowledge or confidence counseling is more important for each participant and follow up with them. To help them learn self-management techniques for overeating.
Study NCT03431831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Contrave
Description: In addition to usual care as described in the comparator intervention, these participants will be prescribed Contrave and raised to the therapeutic dosage within one month. They will be monitored closely for side effects and meds adjusted accordingly.
Study NCT03431831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Contrave and Counseling
Description: This group of participants will receive a combination of all the above interventions including diet/physical activity prescription, motivational interviewing and Contrave.
Study NCT03128138 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPH3127
Description: Drug: SPH3127 Tablet~Drug: Placebo Tablet
Study NCT03229369 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Isolated anatomic ACL reconstruction
Description: Hamstrings free grafts using a two-incision intra-articular Anterior Cruciate ligament (ACL) reconstruction technique. Both ST and gracilis will be prepared with doubled strands, a standard quadrupled graft. The femoral tunnel will be performed in outside-in manner. The tibial tunnel will be drilled in the center of the ACL tibial footprint, sparing the ACL tibial stump, when possible. ACL graft will be first fixed in the femur and then in the tibia, both with an interference screw at 30 degrees of knee flexion.
Study NCT03229369 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Combined Anterior Cruciate Ligament and Anterolateral Ligament reconstruction
Description: Hamstrings free grafts using a two-incision ACL reconstruction with the addition of a gracilis prolongation for ALL reconstruction. ACL graft will exhibit a quadruple strand (tripled ST + single gracilis) and the ALL graft, a single strand with the gracilis prolongation. ALL tibial tunnel will be performed with a 5mm drill, 1cm distal to the articular level, midway from the fibular head and Gerdy Tubercle, crossing the tibia toward its anteromedial cortex, 1cm distal to the ACL tunnel. Femoral ACL and ALL tunnels are coincident and located posterior and proximal to the lateral epicondyle. Intra-articular surgery will be performed in the same manner as comparative group. Gracilis prolongation is routed through the tibial ALL tunnel and then retrieved in the anteromedial aspect of the tibia, 1cm distal to the ACL tunnel entrance. ALL is fixed in full extension and neutral rotation, tying both graft extremities with 3 knots.
Study NCT03432975 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Povidone-Iodine 10%
Description: The side of the mouth receiving the subgingival irrigations of povidone iodine 10% (test group)
Study NCT03432975 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline Solution
Description: The other side of the mouth will be irrigated with a sterile saline solution (control group)
Study NCT02278328 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STX209 (15mg)
Description: A randomized acute dose-response design will be employed with a total study duration of 3 weeks. At each visit, baseline MEG will be obtained followed by acute single-dose drug/placebo administration, followed 60 minutes later by repeat MEG. Each participant will receive a single dose of placebo in random order and a single dose of STX209 from smallest to largest (15mg, and 30mg). MRI and MRS will be performed immediately following MEG to provide an anatomic basis for source localization as well as to assess acute effects of STX209 administration on MRS estimates of GABA and glutamate. The STX209 (15mg) intervention is the low dose
Study NCT02278328 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: A randomized acute dose-response design will be employed with a total study duration of 3 weeks. At each visit, baseline MEG will be obtained followed by acute single-dose drug/placebo administration, followed 60 minutes later by repeat MEG. Each participant will receive a single dose of placebo in random order and a single dose of STX209 from smallest to largest (15mg, and 30mg). MRI and MRS will be performed immediately following MEG to provide an anatomic basis for source localization as well as to assess acute effects of STX209 administration on MRS estimates of GABA and glutamate. The placebo intervention is the non-active placebo control dose
Study NCT02278328 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STX209 (30mg)
Description: A randomized acute dose-response design will be employed with a total study duration of 3 weeks. At each visit, baseline MEG will be obtained followed by acute single-dose drug/placebo administration, followed 60 minutes later by repeat MEG. Each participant will receive a single dose of placebo in random order and a single dose of STX209 from smallest to largest (15mg, and 30mg). MRI and MRS will be performed immediately following MEG to provide an anatomic basis for source localization as well as to assess acute effects of STX209 administration on MRS estimates of GABA and glutamate. The STX209 (30mg) intervention is the high dose
Study NCT04937868 — intervention group
Intervention type: OTHER
Intervention: There are no interventions associated with this study
Description: This study is purely observational, there will be no interventions or changes in care related to patient inclusion in this study.
Study NCT01012830 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Huperzine A
Description: Huperzine A in 200 microgram (mcg) capsules taken twice daily for 8 weeks.
Study NCT04049175 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A
Description: Tablet of CHF 6532
Study NCT04049175 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B
Description: Tablet of CHF 6532
Study NCT04049175 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C
Description: Tablet of CHF 6532
Study NCT04049175 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Treatment D
Description: Tablet of CHF 6532 placebo
Study NCT04315077 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oceanix®
Description: Ingredient contains highly active antioxidant enzymes, including superoxide dismutase (SOD), as well as essential fatty acids, vitamins, amino acids and minerals.
Study NCT04315077 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance Training
Description: 5 days of supervised and programmed whole-body resistance training.
Study NCT04315077 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Resistance Training
Description: 5 days of supervised and programmed whole-body resistance training.
Study NCT02535273 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: load dosage：Intravenous injection dexmedetomidine 1 µg/kg，completed within 10 minutes.
Study NCT02535273 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: local anesthesia：0.67% lidocaine local anesthesia layer by layer to the periosteum at the puncture site，Establish puncture channel, injection 5ml 0.67% lidocaine into the vertebral body through the catheter, and observe 5-10min before operation
Study NCT02535273 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lidocaine
Description: local anesthesia：0.67% lidocaine local anesthesia layer by layer to the periosteum at the puncture site，Establish puncture channel, injection 5ml 0.67% lidocaine into the vertebral body through the catheter, and observe 5-10min before operation
Study NCT02535273 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low-dose Dexmedetomidine
Description: maintenance dose：Intravenous infusion of dexmedetomidine 0.3 μg/kg/min until the end of surgery
Study NCT02535273 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moderate-dose Dexmedetomidine
Description: maintenance dose：Intravenous infusion of dexmedetomidine 0.5 μg/kg/min until the end of surgery
Study NCT02535273 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High-dose Dexmedetomidine
Description: maintenance dose：Intravenous infusion of dexmedetomidine 0.7 μg/kg/min until the end of surgery
Study NCT02535273 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: Intravenous injection normal saline equal quantity，completed within 10 minutes. Intravenous infusion of normal saline 0.125 μg/kg/min until the end of surgery
Study NCT03966833 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IPT-G
Description: 14 weeks of group-based interpersonal therapy (IPT-G)
Study NCT03966833 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Unconditional Cash Transfer
Description: Lump sum cash transfer
Study NCT04899830 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Telepresence robot
Description: From the application installed on a tablet, the patient hospitalized in a center for a period of at least 2 months can start from the center where he is hospitalized the mobile robotic telepresence assistance device installed at home to communicate with his family, his friends, his neighbors,...)
Study NCT03958370 — intervention group
Intervention type: OTHER
Intervention: Fitbit
Description: Fitbit use during physical therapy session
Study NCT04211038 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: inspiratory threshold load device
Description: Before experiment ,every subject use a flanged mouthpiece attached to a manually operated occlusion valve in order to measure maximal inspiratory pressure (MIP)at functional residual capacity .~And then, the healthy subjects will be increased the neural respiratory drive by increasing the pressure in a water-sealed inspiratory threshold loading device. At last, all subjects will do Incremental cycle ergometry test with the assisstance of NPPV.
Study NCT02139033 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Retaine™
Study NCT00568529 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine and Oxaliplatin
Description: Capecitabine 1000mg/m2 Bid d1-14 Oxaliplatin 130mg/m2 d1 q3w
Study NCT00740948 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab (mabthera) Injection
Description: 2 \* 1g of Rituximab at the 1st day and at the 14th day.
Study NCT00740948 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo: NaCl 0.9% or Glucose 5%
Description: 2\* 250ml of NaCl 0.9% or Glucose 5% at the 1st day and at the 14th day.
Study NCT01515410 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DM-1992
Description: 72.5mg carbidopa/230mg levodopa
Study NCT01515410 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sinemet IR
Description: Immediate-release tablet containing 25mg carbidopa and 100mg levodopa
Study NCT00353717 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cetuximab paclitaxel
Description: weekly iv paclitaxel 80 mg/m2 and cetuximab 250 mg /m2
Study NCT02212574 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Lomustine
Description: Chemotherapy Cycle A Lomustine (CCNU) is given by mouth on Day 1.
Study NCT02212574 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Vincristine
Description: Chemotherapy Cycle A Vincristine is given directly into a vein (IV) over one minute or using a minibag over several minutes by some institutions on Days 1, 8, and 15.
Study NCT02212574 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Cisplatin
Description: Chemotherapy Cycle A Cisplatin is given directly into a vein over 8 hours on Day 1.
Study NCT02212574 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Cyclophosphamide
Description: Chemotherapy Cycle B Cyclophosphamide is given into a vein over 1 hour on Days 1 and 2.
Study NCT02212574 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Mesna
Description: Chemotherapy Cycle B MESNA, a drug to protect the bladder from the effects of cyclophosphamide, will be given 15 minutes before each dose of cyclophosphamide and repeated at 3 and 6 hours.